No Data
No Data
Tuoxin Pharmaceutical (301089.SZ) plans to distribute 2.5 yuan for 10 shares to be deducted from interest on May 23
Tuoxin Pharmaceutical (301089.SZ) announced that the company's 2023 equity distribution plan: 2.5 for every 10 shares...
The synthetic biology concept bottomed out and rebounded. In 7 days and 4, Xintiandi surged more than 10%, while Rundu Co., Ltd., Fujilai, Tuoxin Pharmaceuticals, and Rhine Biotech followed suit.
The synthetic biology concept bottomed out and rebounded. In 7 days and 4, Xintiandi surged more than 10%, while Rundu Co., Ltd., Fujilai, Tuoxin Pharmaceuticals, and Rhine Biotech followed suit.
Tuoxin Pharmaceutical (301089.SZ): Actively carry out research on the application of synthetic biology-related technologies in the field of nucleosides and nucleotide products
On May 8, Gelonghui | Tuoxin Pharmaceutical (301089.SZ) announced abnormal stock trading fluctuations. Recently, the company noticed that the Internet and some media published reports on “synthetic biology.” Guided by the principles of systems biology and engineering, synthetic biology takes genomic and biochemical molecular synthesis as the core technology. Through biochemistry, biophysics, and bioinformatics, it continuously designs, transforms, and reshapes biomolecules, biological components, and biological differentiation processes, laying a solid foundation for constructing bioactive biological elements, systems, and artificial cells or organisms. In the field of healthcare, synthesis
Express News | Tuoxin Pharmaceutical: The revenue achieved by synthetic biology-related products accounts for less than 5% of operating income
Synthetic biology concept stocks continued to rise in the afternoon, with Kyodo Pharmaceutical rising and falling 20 cm. Various stocks such as Blue Biotech, Ruifeng Hi-Tech, Lukang Pharmaceutical, Xinghu Technology, Qianjiang Biochemical, and Rhine Biote
Synthetic biology concept stocks continued to rise in the afternoon, with Kyodo Pharmaceutical rising and falling 20 cm. Various stocks such as Blue Biotech, Ruifeng Hi-Tech, Lukang Pharmaceutical, Xinghu Technology, Qianjiang Biochemical, and Rhine Biotech closed. Yiqiao Shenzhou and Tuoxin Pharmaceutical surged more than 14%.
Synthetic organisms are now differentiated! Big bulls have advanced to the 5th straight board, and policy expectations haven't been met yet?
There will be major policies in the future
No Data